Publication

Selective targeting of adenovirus to alpha(v)beta(3) integrins, VEGFR2 and Tie2 endothelial receptors by angio-adenobodies

Haisma, H. J., Kamps, G. K., Bouma, A., Geel, T. M., Rots, M. G., Kariath, A. & Bellu, A. R., 31-May-2010, In : International Journal of Pharmaceutics. 391, 1-2, p. 155-161 7 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Haisma, H. J., Kamps, G. K., Bouma, A., Geel, T. M., Rots, M. G., Kariath, A., & Bellu, A. R. (2010). Selective targeting of adenovirus to alpha(v)beta(3) integrins, VEGFR2 and Tie2 endothelial receptors by angio-adenobodies. International Journal of Pharmaceutics, 391(1-2), 155-161. https://doi.org/10.1016/j.ijpharm.2010.02.032

Author

Haisma, Hidde J. ; Kamps, Gera K. ; Bouma, Arend ; Geel, Tessa M. ; Rots, Marianne G. ; Kariath, Anu ; Bellu, Anna Rita. / Selective targeting of adenovirus to alpha(v)beta(3) integrins, VEGFR2 and Tie2 endothelial receptors by angio-adenobodies. In: International Journal of Pharmaceutics. 2010 ; Vol. 391, No. 1-2. pp. 155-161.

Harvard

Haisma, HJ, Kamps, GK, Bouma, A, Geel, TM, Rots, MG, Kariath, A & Bellu, AR 2010, 'Selective targeting of adenovirus to alpha(v)beta(3) integrins, VEGFR2 and Tie2 endothelial receptors by angio-adenobodies', International Journal of Pharmaceutics, vol. 391, no. 1-2, pp. 155-161. https://doi.org/10.1016/j.ijpharm.2010.02.032

Standard

Selective targeting of adenovirus to alpha(v)beta(3) integrins, VEGFR2 and Tie2 endothelial receptors by angio-adenobodies. / Haisma, Hidde J.; Kamps, Gera K.; Bouma, Arend; Geel, Tessa M.; Rots, Marianne G.; Kariath, Anu; Bellu, Anna Rita.

In: International Journal of Pharmaceutics, Vol. 391, No. 1-2, 31.05.2010, p. 155-161.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Haisma HJ, Kamps GK, Bouma A, Geel TM, Rots MG, Kariath A et al. Selective targeting of adenovirus to alpha(v)beta(3) integrins, VEGFR2 and Tie2 endothelial receptors by angio-adenobodies. International Journal of Pharmaceutics. 2010 May 31;391(1-2):155-161. https://doi.org/10.1016/j.ijpharm.2010.02.032


BibTeX

@article{31e5e2304dae43afb2806bcf2c24fec5,
title = "Selective targeting of adenovirus to alpha(v)beta(3) integrins, VEGFR2 and Tie2 endothelial receptors by angio-adenobodies",
abstract = "Tumor angiogenesis is a prominent mechanism, driving the development and progression of solid tumors and the formation of cancer cell metastasis. Newly formed tumor vessels represent an elective target for the activity and the delivery of cancer therapeutics. We targeted adenovirus (Ad5) to endothelial receptors which are up-regulated during the formation of new blood vessels, to enhance the efficiency of anticancer gene therapy applications.Bifunctional angio-adenobodies were constructed by the fusion of a single chain antibody directed against the adenoviral fiber knob, to different peptides recognizing the alpha(v)beta(3) integrins, VEGFR2 and Tie2 receptors on endothelial cells. The angio-adenobodies were coupled to the adenoviral vector, containing luciferase and GFP as reporter genes.In vitro data showed selective targeting of the Ad5 to the endothelial receptors both in mouse (H5V) and human cell lines (HUVEC). H5V cells, refractory to Ad5 infection, showed high level of luciferase expression when cells were infected with targeted virus. Viral transgene expression increased in HUVEC cells when cells were infected with Ad5 conjugated with angio-adenobody thereby demonstrating the affinity of the peptides for human endothelial cells also. In vivo data obtained from mice bearing a C26 colon carcinoma subcutaneously show viral transgene expression only in tumors infected with angio-adenobodies retargeted adenovirus.The results of the present study demonstrate that endothelial targeted angio-adenobodies represent a versatile tool to direct adenovirus from its native receptors to the integrins a alpha(v)beta(3), VEGFR2 and Tie2 receptors that are fundamental in many angiogenesis related diseases such as cancer. (C) 2010 Elsevier B.V. All rights reserved.",
keywords = "Adenovirus, Angiogenesis, alpha(v)beta(3) Integrins, VEGFR2, Tie2, SINGLE-CHAIN DIABODY, TUMOR ANGIOGENESIS, GENE-TRANSFER, BISPECIFIC ANTIBODIES, THERAPEUTIC TARGET, IN-VIVO, CANCER, VECTORS, CELLS, DELIVERY",
author = "Haisma, {Hidde J.} and Kamps, {Gera K.} and Arend Bouma and Geel, {Tessa M.} and Rots, {Marianne G.} and Anu Kariath and Bellu, {Anna Rita}",
year = "2010",
month = "5",
day = "31",
doi = "10.1016/j.ijpharm.2010.02.032",
language = "English",
volume = "391",
pages = "155--161",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier Bedrijfsinformatie b.v.",
number = "1-2",

}

RIS

TY - JOUR

T1 - Selective targeting of adenovirus to alpha(v)beta(3) integrins, VEGFR2 and Tie2 endothelial receptors by angio-adenobodies

AU - Haisma, Hidde J.

AU - Kamps, Gera K.

AU - Bouma, Arend

AU - Geel, Tessa M.

AU - Rots, Marianne G.

AU - Kariath, Anu

AU - Bellu, Anna Rita

PY - 2010/5/31

Y1 - 2010/5/31

N2 - Tumor angiogenesis is a prominent mechanism, driving the development and progression of solid tumors and the formation of cancer cell metastasis. Newly formed tumor vessels represent an elective target for the activity and the delivery of cancer therapeutics. We targeted adenovirus (Ad5) to endothelial receptors which are up-regulated during the formation of new blood vessels, to enhance the efficiency of anticancer gene therapy applications.Bifunctional angio-adenobodies were constructed by the fusion of a single chain antibody directed against the adenoviral fiber knob, to different peptides recognizing the alpha(v)beta(3) integrins, VEGFR2 and Tie2 receptors on endothelial cells. The angio-adenobodies were coupled to the adenoviral vector, containing luciferase and GFP as reporter genes.In vitro data showed selective targeting of the Ad5 to the endothelial receptors both in mouse (H5V) and human cell lines (HUVEC). H5V cells, refractory to Ad5 infection, showed high level of luciferase expression when cells were infected with targeted virus. Viral transgene expression increased in HUVEC cells when cells were infected with Ad5 conjugated with angio-adenobody thereby demonstrating the affinity of the peptides for human endothelial cells also. In vivo data obtained from mice bearing a C26 colon carcinoma subcutaneously show viral transgene expression only in tumors infected with angio-adenobodies retargeted adenovirus.The results of the present study demonstrate that endothelial targeted angio-adenobodies represent a versatile tool to direct adenovirus from its native receptors to the integrins a alpha(v)beta(3), VEGFR2 and Tie2 receptors that are fundamental in many angiogenesis related diseases such as cancer. (C) 2010 Elsevier B.V. All rights reserved.

AB - Tumor angiogenesis is a prominent mechanism, driving the development and progression of solid tumors and the formation of cancer cell metastasis. Newly formed tumor vessels represent an elective target for the activity and the delivery of cancer therapeutics. We targeted adenovirus (Ad5) to endothelial receptors which are up-regulated during the formation of new blood vessels, to enhance the efficiency of anticancer gene therapy applications.Bifunctional angio-adenobodies were constructed by the fusion of a single chain antibody directed against the adenoviral fiber knob, to different peptides recognizing the alpha(v)beta(3) integrins, VEGFR2 and Tie2 receptors on endothelial cells. The angio-adenobodies were coupled to the adenoviral vector, containing luciferase and GFP as reporter genes.In vitro data showed selective targeting of the Ad5 to the endothelial receptors both in mouse (H5V) and human cell lines (HUVEC). H5V cells, refractory to Ad5 infection, showed high level of luciferase expression when cells were infected with targeted virus. Viral transgene expression increased in HUVEC cells when cells were infected with Ad5 conjugated with angio-adenobody thereby demonstrating the affinity of the peptides for human endothelial cells also. In vivo data obtained from mice bearing a C26 colon carcinoma subcutaneously show viral transgene expression only in tumors infected with angio-adenobodies retargeted adenovirus.The results of the present study demonstrate that endothelial targeted angio-adenobodies represent a versatile tool to direct adenovirus from its native receptors to the integrins a alpha(v)beta(3), VEGFR2 and Tie2 receptors that are fundamental in many angiogenesis related diseases such as cancer. (C) 2010 Elsevier B.V. All rights reserved.

KW - Adenovirus

KW - Angiogenesis

KW - alpha(v)beta(3) Integrins

KW - VEGFR2

KW - Tie2

KW - SINGLE-CHAIN DIABODY

KW - TUMOR ANGIOGENESIS

KW - GENE-TRANSFER

KW - BISPECIFIC ANTIBODIES

KW - THERAPEUTIC TARGET

KW - IN-VIVO

KW - CANCER

KW - VECTORS

KW - CELLS

KW - DELIVERY

U2 - 10.1016/j.ijpharm.2010.02.032

DO - 10.1016/j.ijpharm.2010.02.032

M3 - Article

VL - 391

SP - 155

EP - 161

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

IS - 1-2

ER -

ID: 5097095